Prévisions

L'objectif de cours moyen des analystes est de +5,15€ (+1.070,45%). La médiane est de +5,15€ (+1.070,45%).

Acheter	4
Conserver	1
Vendre	0

Actualités Accéder au fil d'actualités

Arcadia Biosciences secures $4 million through private placement

Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Plus sur de.investing.com
Arcadia Biosciences secures $4 million through private placement

Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Plus sur de.investing.com
Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor

Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, Arcadia Biosciences a réalisé un chiffre d'affaires de 1.26m€ et un bénéfice net de −5.49m€

(EUR)	juin 2026	YoY
Chiffre d'affaires	+1.26m	2,42%
Bénéfice brut	+552.89k	3,28%
Bénéfice net	−5.49m	45,16%
EBITDA	−5.49m	45,65%

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	+683.04k€
Nombre d'actions	1.55m
Plus haut/bas sur 52 semaines	+5,76€ - +0,33€
Dividendes	Non
Bêta	0,55
Ratio P/E	−0,06
Ratio PEG	0,00
Ratio P/B	+1,11
Ratio P/S	+0,17

Profil de l'entreprise

Arcadia Biosciences, Inc. produziert und vermarktet in den Vereinigten Staaten Gesundheits- und Wellnessprodukte auf Pflanzenbasis. Das Unternehmen befasst sich mit der Entwicklung von Pflanzenverbesserungen, vor allem bei Weizen, um die Wirtschaftlichkeit der Landwirtschaft zu verbessern, indem es die Leistung der Pflanzen auf dem Feld erhöht und ihren Wert als Lebensmittelzutaten, Gesundheits- und Wellnessprodukte sowie ihre Eignung für industrielle Anwendungen steigert. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Davis, Kalifornien.

Nom	Arcadia Biosciences
PDG	Thomas J. Schaefer
Siège social	Davis, tx États-Unis
Site web	arcadiabio.com
Secteur	Consommation de base
Industrie	Produits alimentaires
Introduction en bourse	15/05/2015
Employés	8